Novo Nordisk A/S reported 7% gains in both sales and operating profit in 2013, while net profit powered ahead by 18%, prompting directors of the Danish company to vote a 25% dividend increase. Sales for the year were DKK 83.6 billion ($15.1 billion) and operating profit reached DKK 31.5 billion.
